KR101763953B1

KR101763953B1 - Composition for oral cavity

Info

Publication number: KR101763953B1
Application number: KR1020117030164A
Authority: KR
Inventors: 아유미 아마노; 하루오 카도야; 타카시 치카자와; 츠구노 야마구치
Original assignee: 라이온 가부시키가이샤
Priority date: 2009-06-08
Filing date: 2010-06-04
Publication date: 2017-08-14
Also published as: CN102802602A; JP5765225B2; KR20120034656A; JP6207541B2; JP2015110664A; CN102802602B; JPWO2010143589A1; WO2010143589A1

Abstract

(C) POE cured castor oil having an average addition molar number of 10 to 60, an alkyl group of C14 to 18 and an EO average addition mole number of 5 to 8 And (D) a nonionic germicide, wherein the total amount of (A), (B) and (D) is from 0.2 to 1.5 mass% (A), (B) and (C), (C) / (B) + (D) (E) is 0.2 to 1.3 mass%, and (C) / (B) + (E) is in a mass ratio of 8 to 18. According to the present invention, there is provided an oral composition comprising ascorbic acid phosphate ester A salt, a vitamin E or a derivative thereof, and a bactericide are stably and effectively compounded to achieve an excellent periodontal disease preventive or ameliorating effect, and are excellent in storage stability over time.

Description

COMPOSITION FOR ORAL CAVITY [0002]

The present invention relates to an oral composition containing ascorbic acid phosphate or a salt thereof and exhibiting a high periodontal disease prevention or ameliorating effect and also having excellent storage stability over time, Among them, particularly, the effect of improving the amount of excreted amount of saliva (drainage amount) of saliva and oral cavity is high, and the preservation stability of ascorbic acid phosphate or its salt is excellent over time, And a composition for oral cavity which is prevented from discoloration and is excellent in appearance stability.

Periodontal disease can be counted as one of the major causes of loss of teeth, and its prevention is expected to lead to improvements in quality of life (QOL). Most of the periodontal diseases are thought to be infectious diseases caused by bacterial anaerobic gram negative bacillus, and as a result, connective tissue and alveolar bone are destroyed. Clinical findings of this procedure include fever, swelling, bleeding, drainage, and bad breath. There is also a bacterial-host response between the cause and the result.

In chronic periodontal disease, it is known that a cycle of inflammation circulates and tissue destruction is caused by an enzyme derived from a host such as collagenase. In addition, in the tissue, accumulation of neutrophils in periodontal pockets, infiltration of lymphocytes into the tissues of the dental caries, and the like are considered. In the case of dental disease caused by periodontal disease, Plasmodium is reported to be involved.

In the living body, neutrophils have a function of sterilizing bacteria and defending the living body. However, chronic inflammation adversely affects biological tissues due to leakage of cellular components and excessive production of active oxygen. Therefore, it is useful to prevent tissue destruction by active oxygen by using an antioxidant such as ascorbic acid phosphate or its salt. The combination of ascorbic acid phosphate ester or a derivative thereof in the composition for oral cavity is effective for the prevention of periodontal disease, for example, as described in Patent Document 1 and the like. However, ascorbic acid phosphate ester is easily decomposed in a preparation, and there is a problem that storage stability is not sufficient when water or an anionic surfactant is present.

It is also effective to prevent periodontal disease by promoting blood circulation and activating metabolism. Vitamin E (aka tocopherol) derivatives are effective for prevention of periodontal disease because they have antioxidative action in addition to blood circulation promoting effect. It is described in, for example, Patent Document 2 that the combination of the vitamin E derivative in the oral composition is effective for the prevention of periodontal disease. However, there is a problem that it is difficult to dissolve a vitamin E derivative in a preparation and secure storage stability.

In order to stabilize a useful vitamin E derivative in an oral composition by solubilizing it, a surfactant is generally used in combination. However, in this case, the micelle formed by the surfactant becomes too rigid depending on the blending amount of the surfactant, so that the vitamin E derivative contained in the micelle is not released from the target site, There is a problem in that it becomes difficult.

It is described, for example, in Patent Document 3 that a sterilizing agent that exhibits an effect directly by reducing the number of bacteria in the oral cavity caused by inflammation of the dental caries is effective for prevention and improvement of periodontal disease. However, it is common to use a surfactant to stably formulate a microbicide by solubilizing the microbicide in the oral composition. However, depending on the blending amount of the surfactant, the micelle formed by the surfactant becomes too rigid, So that the effect is hardly exerted.

As described above, the ascorbic acid ester or its salt, the vitamin E or its derivative, and the bactericide have still room for improvement in that they can be stably incorporated into the composition for oral cavity and sufficiently exhibit their effects, It is difficult to improve storage stability over time while exhibiting a high effect.

Patent Document 4 discloses a cosmetic composition comprising ascorbic acid phosphoric acid ester salt, a vitamin E derivative and a cationic fungicide, a vitamin E derivative and a cationic fungicide, and polyoxyethylene hardened castor oil (hereinafter, polyoxyethylene is abbreviated as POE). ) Is disclosed in Patent Document 5. Patent Document 5 describes a composition in which a vitamin E derivative and a cationic fungicide are combined with a POE-hardened castor oil in a non-aqueous oral composition. However, it is difficult to say that these compositions have a sufficient periodontal disease-preventing effect, and there is also no description of the average addition mole number of ethylene oxide (hereinafter referred to as EO average addition mole number) of POE-hardened castor oil. Patent Document 6 discloses a composition comprising ascorbic acid phosphate salt, vitamin E derivative and nonionic fungicide in combination as a coating composition for preventing dental caries which does not contain an abrasive. In this composition, vitamin E The solubilization and the compounding stability of the derivative and the nonionic germicide are not sufficient.

(EO average addition molar number 5), POE hardened castor oil (EO average addition molar number 40), and cationic fungicide (EO average molar number 40) as a dentifrice composition containing vitamin E or a derivative thereof, wherein the composition comprises ascorbic acid phosphate ester, vitamin E derivative, vitamin E derivative, and POE stearyl ether Is disclosed in Patent Document 7. However, it is difficult to say that the composition ratio of these components is appropriate. Therefore, the micelles formed by the surfactant become too rigid, and the vitamin E derivatives and fungicide contained in the micelles are not sufficiently released from the target site, There is room for improvement in the manifestation of the effect.

Patent Document 8 describes a composition comprising an ascorbic acid phosphate salt, a vitamin E derivative, a POE alkyl ether and a non-ionic fungicide as an oral composition containing vitamin E or a derivative thereof. However, in this composition, it is difficult to say that the blending ratios of the respective components, particularly the blending ratios of the POE alkyl ether to the vitamin E derivative and the nonionic bactericide, are appropriate, and therefore the stabilization of the vitamin E derivative and the nonionic fungicide is sufficient I can not say. In Patent Document 8, there is no provision concerning the alkyl group portion of the POE alkyl ether, and there is a description that the ascorbic acid derivative stabilizes the vitamin E. However, regarding the simultaneous stabilization of the vitamin E and the ascorbic acid derivative Not shown.

Applicants have found that an oral composition containing POE hardened castor oil having an EO average addition number of 5 to 10 and a pH of 6.5 to 9.0 is added to an oral composition containing an ascorbic acid phosphate ester salt in accordance with Japanese Patent Application No. 2007-326959 2009-149537). This application discloses that in Example 30 there is provided a composition comprising an ascorbic acid phosphate ester salt, a vitamin E derivative, an EO average addition mole number of 5 and 20, a POE hardened castor oil, an EO average addition mole number of POE cetyl ether of 7 and an isopropylmethyl phenol Composition is described. However, this technique improves oral retention and mucosal permeability of ascorbic acid phosphate ester by blending specific POE-hardened castor oil and adjusting the pH, and can effectively exert the effect derived from ascorbic acid phosphate ester salt And the technical idea is different from the present invention.

In addition, none of the technologies described here have a description of a technique for restraining bad breath caused by periodontal disease, and technical ideas and actions and effects based on the constitution of the present invention can not be derived from these techniques.

Therefore, it is desired to develop an oral composition which has the above-mentioned problems, has a prevention or amelioration effect of higher periodontal disease, and is also excellent in storage stability over time, and appearance stability represented by prevention of separation and discoloration.

Patent Document 1: Japanese Patent Application Laid-Open No. 2007-169201 Patent Document 2: JP-A-2005-350483 Patent Document 3: JP-A-2006-312588 Patent Document 4: JP-A-2005-239654 Patent Document 5: JP-A-2002-114656 Patent Document 6: Japanese Patent Application Laid-Open No. 2005-187333 Patent Document 7: JP-A-2005-247786 Patent Document 8: Japanese Patent Application Laid-Open No. 2004-323488

Non-Patent Document 1: "Thinking about the health of periodontal disease and whole body - bridging to a new health science", Lion Dental Hygiene Research Institute, Dentistry Publishing Co., 2004, P. 221 Non-Patent Document 2: "Thinking about the health of periodontal disease and whole body - Bridging to new health science, Lion Dental Hygiene Research Institute, Dentistry Publishing Co., 2004, P. 116

SUMMARY OF THE INVENTION The present invention has been made in view of the above circumstances, and it is an object of the present invention to provide a method for preventing or ameliorating periodontal disease by effectively and stably mixing ascorbic acid phosphate or its salt, vitamin E or a derivative thereof, It is an object of the present invention to provide an oral composition excellent in storage stability.

The inventors of the present invention have found that (A) an ascorbic acid phosphate or a salt thereof, (B) vitamin E or a derivative thereof, and (C) At least one surfactant selected from POE cured castor oil of 60 moles, POE alkyl ether having alkyl group of 14 to 18 carbon atoms and EO average addition mole number of 5 to 8 moles, and alkyl glucoside of alkyl group of 10 to 14 carbon atoms (D) a non-ionic fungicide or (E) a cationic fungicide as a bactericide, and the amounts and the blending ratios of these components are set in the corresponding ranges as shown below, Prevention or amelioration effect, and was excellent in storage stability over time.

INDUSTRIAL APPLICABILITY According to the present invention, it is possible to provide a composition for oral administration, which comprises a combination of ascorbic acid phosphate or a salt thereof, vitamin E or a derivative thereof, and a bactericide at the same time, , GCF) and a high bactericidal effect on periodontal pathogens, and the prevention and improvement of periodontal disease is markedly improved. In addition, ascorbic acid phosphate or its salt and vitamin E or a derivative thereof is stably compounded at the same time over a long period of time, and separation or discoloration does not occur with time, and storage stability with time is also excellent.

That is, according to the present invention, with the above-described constitution, it is possible to obtain an oral composition having both a high periodontal disease improving effect and a long-term storage stability which can not be achieved by conventional techniques. It is known that ascorbic acid phosphate ester or its salt, vitamin E or a derivative thereof, or a bactericide is effective for prevention or improvement of periodontal disease. In the present invention, however, These compounds act synergistically in appropriate amounts and ratios to exhibit a high effect of improving the amount of halitosis or GCF among the symptoms accompanying periodontal disease and exhibiting a high sterilization effect on periodontal pathogens . Further, in the present invention, ascorbic acid phosphate ester or its salt and vitamin E or its derivative are stably retained even after storage for a long period of time, so that the effect derived from these components can be stably expressed with a lapse of time, Separation and discoloration do not occur in storage, and good appearance stability is obtained. Such an action and effect of the present invention are unusual in that it can not be achieved when one of the essential components of the present invention is lacking, or when the amounts and ratios of the components are inadequate.

In addition, halitosis caused by periodontal disease is produced by gram-negative bacteria in the oral cavity. A sulfur-containing amino acid serving as a substrate is supplied from the GCF or blood. When the periodontal disease occurs, the amount of GCF is increased, that is, bad taste is produced because the substrate of halitosis is increased (Non-Patent Document 1). In the present invention, the effect of improving the periodontal disease is exerted, the amount of the sulfurous acid amino acid, which is a substrate of halitosis production, is decreased due to the decrease of the amount of GCF, and the bactericidal agent is synergistically effective in sterilizing halophilic acid live bacteria. And it is presumed that it suppresses bad breath originated from periodontal disease. This GCF is present in dental caries and teeth, and positively inhibits the intrusion of foreign substances such as bacteria and toxins by an antibody component or the like, and contributes to biological defense. On the other hand, interferon (hereinafter abbreviated as IL) ) -1, IL-6, IL-8, and the like have been implicated in periodontal disease (Non-Patent Document 2). In the present invention, it is presumed that the periodontal disease is remarkably improved, the amount of GCF once increased and the substrate of halitosis are decreased, and that the sterilizing agent sterilizes the live bacteria of halophilicity, so that halitosis can be suppressed . In addition, the amount of GCF is increased as the periodontal disease occurs, and decreases as it improves. Therefore, the amount of GCF is used as an index for evaluating the severity and improvement of periodontal disease.

The composition of the present invention may further comprise (F) at least one active ingredient selected from glycyrrhetinic acid,? -Aminocaproic acid, glycyrrhizinate, tranexamic acid, yellow white extract and allantoin to prevent or ameliorate periodontal disease The effect is further improved and the amount of GCF that has been increasing with the incidence of periodontal disease can be more effectively reduced.

Accordingly, the present invention provides the oral composition described below.

Claim 1:

(A) ascorbic acid phosphate ester or a salt thereof,

(B) vitamin E or a derivative thereof,

(C) a polyoxyethylene hydrogenated castor oil having an average addition mole number of ethylene oxide of 10 to 60 moles, a polyoxyethylene alkyl ether having an alkyl group of 14 to 18 carbon atoms and an average addition mole number of ethylene oxide of 5 to 8 moles, At least one surfactant selected from alkyl glucosides having 10 to 14 carbon atoms,

(D) Nonionic disinfectant

(A), (B) and (D) is from 0.2 to 1.5% by mass and the ratio of (C) / (B) + (D) &Lt; / RTI >

Claim 2:

The oral composition according to claim 1, wherein the nonionic germicide (D) is isopropylmethylphenol or triclosan.

Claim 3:

(A) ascorbic acid phosphate ester or a salt thereof,

(B) vitamin E or a derivative thereof,

(E) Cationic fungicide

(C) / (B) + (E) in a mass ratio of 8 to 18, wherein the total content of the components (A), (B) and (E) is from 0.2 to 1.3 mass% &Lt; / RTI >

[Claim 4]

The oral composition according to claim 3, wherein the (E) cationic bactericide is at least one selected from cetylpyridinium chloride, benzethonium chloride, benzalkonium chloride, chlorhexidine gluconate, and chlorhexidine hydrochloride.

Claim 5:

(C) / (B) + ((D) or (E)) in which the total content of the component (A), the component (B) and the component (D) ] Is from 8 to 15 in terms of a mass ratio. The oral composition according to any one of claims 1 to 4,

[Claim 6]

The composition according to any one of claims 1 to 5, further comprising (F) at least one member selected from glycyrrhetinic acid,? -Aminocaproic acid, glycyrrhizinate, tranexamic acid, yellow white extract and allantoin &Lt; / RTI >

INDUSTRIAL APPLICABILITY The oral composition of the present invention exhibits a high effect of improving the amount of halitosis or an increase in the amount of GCF and a high germicidal effect on periodontal pathogens among the symptoms accompanying periodontal disease and is excellent in storage stability over time , And is also excellent in appearance stability represented by separation or discoloration. Further, by mixing the component (F), a suppressing effect of a higher GCF amount increase is exerted. Therefore, the oral composition of the present invention is useful for prevention or improvement of periodontal disease.

BEST MODE FOR CARRYING OUT THE INVENTION The oral composition of the present invention comprises (A) ascorbic acid phosphate ester or a salt thereof, (B) vitamin E or a derivative thereof, (C) a specific surfactant, (D) a nonionic germicide or (E) a cationic germicide.

(A) The ascorbic acid phosphoric acid ester and its salt are obtained by esterification of one or more of hydroxyl groups at positions 2, 3, 5 and 6 of ascorbic acid with a compound of phosphoric acid, polyphosphoric acid or the like And examples thereof include ascorbic acid-2-phosphate ester, ascorbic acid-3-phosphate ester, ascorbic acid-6-phosphate ester and ascorbic acid-2-polyphosphoric ester. Examples of salts include alkali metal salts such as sodium salt, potassium salt, calcium salt and magnesium salt, and alkaline earth metal salts. In particular, magnesium salt or sodium salt of ascorbic acid phosphate ester, that is, magnesium L-ascorbyl phosphate and sodium L-ascorbyl phosphate, are preferably used in oral cavity or in view of prevention of dental caries inflammation. Is used.

Ascorbic acid phosphate and salts thereof are commercially available products, specifically, L-ascorbyl phosphate is commercially available under the trade name of Asakoruben acid PM, Wako Pure Chemical Industries, Ltd. (trade name: L- Ascorbyl sodium phosphate can be obtained from DSM Nutrition Co., Ltd. (trade name: STAY-C50), BASF Japan Co., Ltd. (trade name: L-ascorbyl sodium phosphate) Can be used.

The amount of the ascorbic acid phosphate or its salt is preferably 0.05 to 0.8% (mass% or less, more preferably 0.1 to 0.5%) of the entire composition from the viewpoints of periodontal disease prevention effect and storage stability with time. If the blending amount is less than 0.05%, the effect of preventing or improving periodontal disease can not be sufficiently obtained. If the blending amount exceeds 0.8%, discoloration may occur with time, and a stimulation may be generated to adversely affect the feeling of use.

(B) Vitamin E or a derivative thereof (hereinafter, vitamin E is abbreviated as VE) includes d-alpha-tocopherol, dl- alpha -tocopherol, beta -tocopherol,? -Tocopherol,? -Tocopherol, Esters or salts with organic acids such as nicotinic acid, succinic acid, linolenic acid and the like can be used. Examples of the VE derivatives include dicarboxylic acid such as d-alpha-tocopherol acetate, dl-alpha -tocopherol acetate, d-alpha-tocopherol acetate, dicot alpha-tocopherol, nicotinic acid dl- alpha -tocopherol, succinic acid d- d-α-tocopherol, dl-α-tocopherol linolenic acid, and calcium tocopherol succinate.

Vitamin E or a derivative thereof is preferably a vitamin E or a derivative thereof which has a high physiological activity and exhibits a color tone or appearance of a preparation from colorless to pale yellow (in particular, dl-α-tocopherol, dl-α-tocopherol acetate, nicotinic acid dl -? - tocopherol. The VE and its derivatives may be used singly or in combination of two or more.

As the VE or the derivative thereof, there can be used those which are suitable for old cosmetic raw material standards (Jangwongi) or quasi-medical raw material specifications 2006, and those which are usually used for cosmetic and oral compositions can be used. As the VE or the derivative thereof, a commercially available product sold by DSM Nutrition Co., Ltd., Ezafudo Chemical, BASF Japan, or the like can be used.

The blending amount of VE or its derivative is preferably 0.05 to 0.5%, particularly 0.05 to 0.3%, in terms of the periodic disease prevention effect and storage stability with time. If the blending amount is less than 0.05%, the effect of preventing or improving periodontal disease is not sufficiently obtained. If the blending amount is more than 0.5%, the solubilization in the preparation becomes difficult and separation or discoloration occurs with time, have.

(C) is a POE cured castor oil having an EO average addition mole number of 5 to 8 moles and an average addition mole number of 10 to 60 moles of POE alkyl ether having 14 to 18 carbon atoms in the alkyl group, 14 < / RTI > alkyl glucosides.

The POE alkyl ether preferably has an alkyl group having 14 to 18 carbon atoms, preferably 16 to 18 carbon atoms. If the number of carbon atoms in the alkyl group is less than 14, the solubility of the oil soluble component is insufficient because of the low lipophilic property, and sufficient foamability can not be obtained. If the number of carbon atoms exceeds 18, the solubility of the oil soluble component It becomes insufficient, and a unique odd taste or feeling is produced during use of the preparation. Specific examples of the POE alkyl ether include POE cetyl ether, POE myristyl ether, and POE stearyl ether, and POE stearyl ether is particularly suitable.

The EO average addition mole number of the POE alkyl ether is in the range of 5 to 8 moles. When the EO average addition mole number is lower than 5 moles, the solubilizing ability is inadequate, so that the liquid component of the oiliness is separated in the preparation, and when it exceeds 8 moles, it is unusual and deteriorates in the expression of the flavor.

As such POE alkyl ethers, commercially available products such as EMALEX 105, 107, 605 and 608 of Japan Emulsion Co., Ltd. can be used.

As POE hardened castor oil, those having an EO average addition mole number of 10 to 60 can be used. For example, it is particularly preferable that the EO average addition molar number is in the range of 10 to 30 when it is used in a softener, and the EO average addition mole number is preferably 40 to 60 when it is used in a detergent. When the EO average addition mole number is less than 10 moles, the solubilizing ability of the oil soluble component is insufficient, and in particular, when it is prepared as a softener, a rough surface at low temperature is generated and the appearance is sometimes deteriorated. When the amount is more than 60 moles, the solubilizing ability of an effective component such as vitamin E or a derivative thereof or a fungicide, and further, an effective oil soluble ingredient and a flavor ingredient is insufficient, and the oil soluble ingredient may be separated.

As such POE-hardened castor oil, commercially available products such as NIKKOL HCO-10, HCO-20, HCO-30, HCO-40, HCO-50 and HCO-60 of Nikko Chemicals KK can be used.

As the alkyl glucoside, those having 10 to 14, preferably 10 to 12 carbon atoms in the alkyl group are used. When the number of carbon atoms is less than 10, sufficient foamability can not be obtained. When the number of carbon atoms is more than 14, unusual taste or feel is generated.

As such alkyl glucosides, commercially available products such as Plant Care 1200UP and Plant Care 2000UP of Cogunis can be used.

As the component (C), the above-mentioned POE alkyl ether, POE-hardened castor oil, or alkyl glucoside may be blended, or two or more kinds selected from POE alkyl ether, POE-cured hemicellulose oil and alkyl glucoside may be combined It may be blended. When two or more of them are used in combination, it is preferable to use POE alkyl ether in combination with POE-hardened castor oil. In the case of a skimmer such as a kneader, a POE-hardened castor oil having an alkyl group of 16 to 18 carbon atoms, an EO average addition mole number of 5 to 8 mol and an EO average addition mole number of 10 to 30 In a mass ratio of 3: 7 to 7: 3. Particularly, when POE alkyl ethers having an alkyl group of 16 to 18 carbon atoms and an EO addition mole number of 6 or less are used, POE cured castor oils having an EO average addition mole number of 20 to 40 are used in combination, When POE-hardened castor oil is used, it is most preferable that the POE alkyl ether having an alkyl group of 16 to 18 and an EO average addition mole number of 7 to 8 is used in combination in view of the stability of the component (B) and the separation inhibition.

The total amount of the nonionic surfactant as the component (C) is preferably from 0.5 to 5%, particularly preferably from 0.5 to 3%, from the viewpoints of solubility of the oil-soluble component, effect of the oil-soluble component, and usability. When the blending amount is less than 0.5%, the solubilizing ability of the oil soluble component is not sufficiently obtained, and the storage stability is insufficient because the VE or its derivative and the nonionic bactericide are not sufficiently solubilized. When the amount of the component (C) exceeds 5%, micelles due to the component (C) become too rigid, and the effective ingredient of the usability contained in the micelles is not released into the oral cavity. , A bitter taste or irritation may occur and the preparation may not be applied to the oral cavity for a long time. Particularly, in the case of a skirt, it is most preferable that the blending amount is 1 to 3% because a large amount of an oil-soluble ingredient such as a fragrance is blended.

Further, the composition of the present invention is blended with (D) a nonionic bactericide or (E) a cationic bactericide as a bactericide.

Examples of the nonionic germicide (D) include isopropylmethylphenol, triclosanic acid, hinokitiol, phenol and the like. One or more of these can be used. In particular, from the viewpoints of sterilizing power and taste, Phenol, and triclosan are preferred. (Trade name: isopropylmethylphenol), and triclosan can be obtained from Chiba Specialty Chemicals Co. (trade name: Irugacan DP-300) and the like. The nonionic germicide may be a commercially available product, .

The blending amount of the nonionic germicide is preferably 0.01 to 0.3%, particularly 0.02 to 0.1%, of the total composition from the viewpoint of the periodontal disease prevention effect and feeling of use. When the blending amount is less than 0.01%, it is inferior to the sterilizing effect, and the effect of improving periodontal disease and bad breath by sterilization is not sufficiently obtained. When the blending amount exceeds 0.3%, the blending amount is not solubilized. , Bitterness may occur, and the feeling may be deteriorated.

Examples of the cationic fungicide (E) include quaternary ammonium compounds such as cetylpyridinium chloride, benzethonium chloride, benzalkonium chloride and decalinium chloride, bisguanide compounds such as chlorhexidine gluconate and chlorhexidine hydrochloride, Ethylglycine, and the like, and one or more of these may be used. In particular, quaternary ammonium-based or bisguanide-based ones are preferable from the viewpoints of sterilizing power and taste. Among them, cetylpyridinium chloride, benzethonium chloride, Benzalkonium chloride, chlorhexidine gluconate, and chlorhexidine hydrochloride are most preferable.

Cationic pyridinium chloride is commercially available from Wako Pure Chemical Industries, Ltd. (trade name: cetylpyridinium chloride), benzethonium chloride is manufactured by Longer Japan Co. (trade name: Hiamin 1622), and benzalkonium chloride is commercially available from Amakasu Chemical Industries Co., (Trade name: 10% benzalkonium chloride solution), Sumitomo Pharmaceutical Co., Ltd. (trade name: Hibitens gulconeto liquid) and chlorhexidine hydrochloride were purchased from Sumitomo Pharmaceutical Co., Ltd. (trade name: 5% Hibiten liquid) can do.

The compounding amount of the cationic bactericide is preferably from 0.001 to 0.1%, particularly preferably from 0.01 to 0.05%, from the viewpoint of the periodontal disease preventive effect and feeling of use. If the blending amount is less than 0.001%, the sterilizing effect is inferior and the periodontal disease and bad breath improving effect by sterilization is not sufficiently obtained. If the blending amount is more than 0.1%, bitterness and the like may be produced, and the feeling of use may deteriorate or discoloration may occur.

In the present invention, the total amount of the (A) ascorbic acid phosphate ester or its salt, (B) the vitamin E or its derivative, and (D) the nonionic bactericide is, in terms of prevention of periodontal disease and appearance stability, Is 0.2 to 1.5%, particularly preferably 0.2 to 1.0%. If the total amount is less than 0.2%, the periodontal disease preventive effect is not sufficiently exhibited. If the total amount exceeds 1.5%, the components (A), (B) or (D) are separated with time or discolored.

The mixing ratio of the components (C), (B) and (D) is preferably (C) / ((B) + (D)) in view of prevention of periodontal disease, stability of component (B) Is in the range of 8 to 20, and particularly preferably in the range of 8 to 15. If the blending ratio is less than 8, the components (B) and (D) are not solubilized, resulting in inadequate storage stability or separation in the preparation, and if it exceeds 20, the micelle due to the component (C) becomes too rigid , The components (B) and (D) contained in the micelles are not released into the oral cavity, so that the periodontal disease prevention effect is not sufficiently exerted.

In the present invention, the total amount of the (A) ascorbic acid phosphate ester or its salt, (B) the vitamin E or its derivative, and (E) the cationic fungicide, 0.2 to 1.3% of the total amount, and particularly preferably 0.2 to 1.0%. If the total amount is less than 0.2%, the periodontal disease preventive effect is not sufficiently exhibited. If the total amount exceeds 1.3%, the components (A), (B) or (E) are separated with time or discolored.

The mixing ratio of the components (C), (B) and (E) is preferably in the range of (C) / (B) + (E) in terms of prevention of periodontal disease, stability of component The mass ratio is preferably 8 to 18, particularly preferably 8 to 15. If the blending ratio is less than 8, the component (B) is not solubilized, the storage stability becomes insufficient, and separation occurs in the preparation. If the blending ratio exceeds 18, the micelle due to the component (C) becomes too rigid, The components (B) and (E) are not released into the oral cavity, and the effects derived from these components are not sufficiently exerted.

Particularly in the present invention, it is preferable that the total content of the component (A), the component (B), the component (D) or the component (E) is 0.2 to 1.0% (E)) is 8 to 15 in mass ratio, it is most effective because the effect of preventing or improving periodontal disease is further improved and storage stability with time is also excellent.

The oral composition of the present invention may further comprise (F) one or more active ingredients selected from glycyrrhetinic acid,? -Aminocaproic acid, glycyrrhizinate, tranexamic acid, yellow white extract and allantoin . (F), it is possible to further improve the periodontal disease prevention / improvement effect, and as a result, leaching of GCF accompanied with periodontal disease can be suppressed even more. Allantoin derivatives include allantoin, allantoin chlorohydroxyaluminum, and allantoin dihydroxy aluminum (also known as aldoxa).

The component (F) may be a natural product, a synthetic product, or a commercially available product. Specifically, glycyrrhetinic acid is commercially available from Maruzen Pharmaceuticals (trade name: glycyrrhetinic acid), ε-aminocaproic acid is commercially available from CHEMICAL CHEMICALS (trade name: Epsilon-aminocaproic acid) and Ajinomoto (trade name: Epsilon-aminocaproic acid) (Trade name: Glycyrrhizin K2), Alps Chemical Industries (trade name: glycyrrhizic acid 2K), Tranexamic acid is commercially available as First Palmeteca (trade name: Tranexamic acid), Glycyrrhizin acid Allantoin is sold by DSM Nutrition Co., Ltd. (trade name: Allantoin), allantoin chlorohydroxy aluminum is sold by Merck Co., Ltd. (trade name: Nippon Kayaku Co., Ltd.) : RonaCare Allantoin (registered trademark)), and allantoin dihydroxy aluminum available from Natural Fine Chemicals (trade name: ALDA).

When the component (F) is blended, the blending amount thereof is preferably from 0.01 to 0.5%, particularly preferably from 0.01 to 0.3%, from the viewpoint of the periodontal disease-preventing effect and feeling of use. When the blending amount is less than 0.01%, the effect of inhibiting the increase of the amount of GCF is not satisfactorily exhibited and the improvement of the periodontal disease prevention effect is not sufficiently obtained. If the blending amount exceeds 0.5%, a bitter taste may be produced.

The oral composition of the present invention may also contain dextranase. By combining dextranase, plaque, which is one of the causes of periodontal disease, can be easily broken down and removed, and the prevention and improvement effect of periodontal disease can be further enhanced.

Dextranase is an enzyme produced by the genus Ketomium, Penicillium, Aspergillus, Spicaria, Lactobacillus, and Cell Vibrio, and has a plasgolytic action. Dextranase can be obtained from Dai-riko Pharmaceutical Co., Ltd. (trade name: dextranase).

When dextranase is formulated, its blending amount is preferably from 2 to 200 units / g, particularly preferably from 10 to 50 units / g, from the viewpoint of a plaque decomposition effect and a formulation stability. One dextranase unit is an amount of dextranase in which a free reducing sugar equivalent to 1 占 퐉 ol of glucose is produced per minute for a reaction when dextran is used as a substrate. For example, in the case of using dextranase of 13,000 units / g product (product), the blending amount thereof is preferably 0.016 to 1.5%, particularly 0.08 to 0.38% of the whole composition. If the blending amount is less than 2 units / g, the blending effect, for example, a sufficient plaque removing effect may not be obtained. If the blending amount is more than 200 units / g, discoloration of the preparation may occur.

The oral composition of the present invention may further contain a fluorine ion source. By combining the fluoride ion source, it is possible to strengthen the hemorrhoids of the root portion exposed as a result of dental decomposition due to periodontal disease and to prevent or inhibit the development or progression of root caries . Since the root portion has a property of dissolving in acid, it is likely to become a caries, but in the case of healthy caring, since the root portion is inside the caring, there is no contact with the mountain and no caries. However, when the periodontal disease recovers due to the periodontal disease, the root portion is exposed, dissolves in contact with the acid, and becomes a caries. This is called "hardened dental caries". In the present invention, by mixing a fluorine ion source, the tooth root of the root portion is strengthened and hardly dissolved in the acid, and the expression or progression of the hardened caries can be prevented or suppressed.

Examples of the fluorine ion source include sodium fluoride, potassium fluoride, ammonium fluoride, tin fluoride, amine fluoride, sodium monofluorophosphate, potassium monofluorophosphate, sodium fluoride, calcium silicon fluoride and the like. These may be used alone or in combination of two or more, and sodium fluoride and sodium monofluorophosphate are particularly preferable in terms of taste. The fluorine ion source may be a commercially available one, for example, Sterachemi Pasa for sodium fluoride, and Sodium Monofluorophosphate available from Albright & Wilson Co.,

When a fluorine ion source is compounded, the blending amount thereof is preferably from 0.02 to 10.0%, particularly preferably from 0.05 to 1.5% of the whole composition in terms of proximal caries prevention effect and solubility. For example, in the case of sodium fluoride, the content is preferably 0.02 to 3.0%, particularly 0.05 to 1.5%, in the case of sodium monofluorophosphate, 0.05 to 10.0%, particularly 0.1 to 5.0%, in the case of tin fluoride, 0.01 to 1.6% 0.03 to 0.8% is preferable. When the blending amount of the fluorine ion source is less than 0.02%, a satisfactory blending effect may not be obtained. When the blending amount is more than 10.0%, solubilization in a preparation may become difficult.

The oral composition of the present invention can be used as a dental composition such as a soft skirt, a soft skirt, a foam skirt, a liquid skirt, a liquid skirt, a mouthwash, a mouthwash, Tablets, chewing gums, and the like, and can be appropriately prepared as a skimmed preparations or a salvage preparation.

In this case, the oral composition may be formulated in accordance with various formulations, in addition to the above-mentioned components, in addition to the above-mentioned known ingredients in such a range as not to impair the effects of the present invention. Examples of the optional components that can be blended include a surfactant other than the above-mentioned component (C), a sweetener, a preservative, various effective components, a pH adjuster, a coloring agent, a perfume, etc. in combination with a polishing agent, a wetting agent, And can be prepared by mixing these components.

Examples of the abrasive include silica-based abrasives such as silica gel, precipitated silica, aluminosilicate, zirconosilicate, and amorphous anhydrous silicic acid, dibasic calcium phosphate dihydrate, dibasic calcium phosphate anhydride, tribasic calcium phosphate, Calcium carbonate, calcium phosphate, calcium pyrophosphate, aluminum hydroxide, alumina, titanium dioxide, insoluble calcium metaphosphate, hard calcium carbonate, heavy calcium carbonate, magnesium carbonate, magnesium phosphate, zeolite, polymethylmethacrylate, nylon powder, silk powder , Cellulose powder, glucocomannan, and the like.

The blending amount of the abrasive is usually 0 to 50%, and in the case of the dentifrice composition, it is preferably 2 to 40%.

Examples of the wetting agent include sugar alcohols such as sorbitol, glycerin, propylene glycol, polyethylene glycol having an average molecular weight of 200 to 6000, 1,3-butylene glycol, xylitol, erythritol, lactitol, palatinose, palatinit, trehalose, , And polyhydric alcohols (the blending amount is usually 0 to 50%, particularly 5 to 45%).

As the binder, there may be mentioned xanthan gum, sodium polyacrylate, carrageenan, sodium alginate, propylene glycol alginate, carboxyvinyl polymer, tragacanth gum, guar gum, hydroxypropyl guar gum, Tara rubber, locust bean gum, But are not limited to, cellulose derivatives such as sodium carboxymethylcellulose, sodium carboxymethylcellulose, sodium carboxymethylcellulose, sodium carboxymethylcellulose, hydroxyethylcellulose, hydroxyethylcellulose, hydroxyethylcellulose, , Polyvinyl alcohol, polyvinylpyrrolidone, pullulan, thick viscous silica, non-rubber, smectite, laponite, montmorillonite, bentonite and the like (blended amount is usually 0 to 5%, especially 0.1 to 5%).

As the solvent, water is generally used. When water is contained, the blending amount is usually 1 to 99%, and the dentifrice composition is usually blended at 1 to 50%. As the solvent, a lower alcohol such as ethanol may be blended, and the blending amount of the lower alcohol is suitably 0.1 to 30%. The total amount of the solvent is usually from 0 to 99%.

As the surfactant, other nonionic surfactants, anionic surfactants, cationic surfactants, and amphoteric surfactants may be added in addition to the surfactant of the component (C). Specific examples include POE polyoxypropylene copolymers, sucrose fatty acid esters, sorbitan fatty acid esters, glycerin fatty acid esters, polyglycerin fatty acid esters, POE sorbitan fatty acid esters, POE sorbit fatty acid esters, POE glycerin fatty acid esters, POE glycol fatty acid esters , POE alkyl ether phosphoric acid and salts thereof, POE alkyl ether sulfate, POE phytosterol and phytostanol, POE alkyl phenyl ether phosphoric acid and salts thereof, POE lanolin and lanolin alcohol, POE alkyl amine and fatty acid amide, POE alkylphenyl formaldehyde condensate , POE polyoxypropylene alkyl ethers, POE alkyl phenyl ethers and fatty acid ethanol amides, polyethylene glycol fatty acid esters and the like, and nonionic surfactants such as octyl sulfuric acid, decyl sulfuric acid, lauryl sulfuric acid, myristyl sulfuric acid, palmitic sulfuric acid, These alkali metal salts (sodium, potassium, lithium, etc. Alkylsulfuric acid ester or salt thereof such as alkali metal salt of N-myristoyl sarcosinate, sodium N-lauroyl sarcosinate, sodium N-myristoyl sarcosinate, sodium dodecylbenzenesulfonate, hydrogenated coconut fatty acid monoglyceride mono N-acylglutamates such as sodium sulfate, sodium laurylsulfoacetate and sodium N-palmitoylglutamate, sodium N-methyl-N-acyltaurine, sodium N-methyl-N-acylalanine, sodium alpha -olefin sulfonate, Cationic surfactants such as alkylammonium and alkylbenzylammonium salts; amphoteric surfactants such as betaine acetate, imidazolinium betaine and fatty acid amidepropylbetaine; and the like. The blending amount of these surfactants is usually from 0 to 5%. In particular, the nonionic surfactant other than the component (C) may not be blended, and may be 0%.

The amount of the surfactant as the optional component is preferably in the range of 0.5 to 6% of the total amount of the component (C) and the surfactant.

Examples of the sweetening agent include sodium saccharin, stevioside, stevia extract, paramethoxy cinnamic aldehyde, neohespyridyl hydrocolcon, perylartin, tau martin, sucralose, acesulfame potassium, and aspartame.

Examples of the preservative include parabens (p-oxybenzoic acid ester) such as methylparaben, butylparaben, and ethylparaben, benzoic acid and salts thereof, salicylic acid and esters or salts thereof, and the like.

Examples of the effective ingredient include those other than the above components (A), (B), (D), (E), and (F), dextranase and a source of fluoride ions such as ascorbic acid and its derivatives, riboflavin , Vitamins such as pyridoxine hydrochloride, cyanocobalamin,? -Carotene, ergocalciferol, menadione and ubiquinone, phthalocyanine, gold, hammamelis, cloves, camomile, latinia, myrrh, Enzymes such as mutagens, lysozyme, amylase, protease, lytic enzyme and superoxide dismutase; salts such as sodium chloride, potassium nitrate, sodium polyphosphate, carbonate, bicarbonate and sesquicarbonate; Dihydrocholesterol,? -Bisabolol, azulene, methoxyethylene / maleic anhydride copolymer, trichlorocarbonylid, alanine, glycine, proline, L-arginine, sodium L-aspartate, trimethylglycine, copper Copper chlorophyllin Sodium gluconate, copper, zinc chloride, zinc citrate, zeolite, water-soluble inorganic phosphoric acid compounds, aluminum lactate, etc. may be added alone or in combination of two or more. The amount of the effective ingredient added may be an effective amount within a range not hindering the effect of the present invention.

Examples of the pH adjuster include various salts such as citric acid, malic acid, lactic acid, tartaric acid, succinic acid, acetic acid, phosphoric acid, pyrophosphoric acid, copper styrenic acid, potassium salts thereof, sodium salts and ammonium salts thereof, sodium hydroxide and hydrochloric acid. These may be compounded singly or in combination of two or more such that the pH of the composition is in the range of 5 to 9 (the blending amount is usually 0 to 2%).

Examples of the colorant include red No. 2, red No. 3, red No. 225, red No. 226, No. 4, No. 5, No. 205, No. 1, No. 2, No. 201, Etc., safflower dye, gardenia dye, cochineal dye, anato dye, iron stalk, mica titanium, titanium oxide and the like.

Examples of the perfume include at least one selected from the group consisting of peppermint oil, spearmint oil, anise oil, eucalyptus oil, wintergreen oil, cassis oil, clove oil, time oil, sage oil, lemon oil, orange oil, peppermint oil, cardamon oil, , Lemon oil, lavender oil, rosemary oil, laurel oil, camomile oil, caraway oil, marjoram oil, bayu, lemongrass oil, olganan oil, pine needle oil, neroli oil, rose oil, jasmine oil, iris concrete, Natural fragrance such as lute peppermint, absolute rose and orange flower, and a natural flavor such as a natural flavor such as a processed fragrance (a preliminary portion cut, a wake cut, a liquid, a liquid extraction, an essence, 3-l-menthoxypropane-l, 2-diol, linalool, linalool acetate, limonene, menton, cetyl alcohol, Menthyl acetate, N-substituted-parramentane-3-carboxamide, pinene, octylaldehyde , Ethyl acetate, ethyl butylate, allyl cyclohexane propionate, methyl anthranylate, ethyl methylphenyl glycidate, vanillin, undecalactone, hexanal, ethyl alcohol (Single product) flavor such as propyl alcohol, butanol, isoamyl alcohol, hexenol, dimethyl sulfide, cyclotene, furfural, trimethylpyrazine, ethyl lactate and ethyl thioacetate, A combination flavor such as a flavor, a banana flavor, a pineapple flavor, a grapeflavor, a mango flavor, a butter flavor, a milk flavor, a fruity mix flavor, and a tropical fruit flavor. A perfume material can be used, and is not limited to the perfume of the examples. The blending amount is not particularly limited, but it is preferable that the above-mentioned perfume material is used in an amount of 0.000001 to 1% in the formulation. In addition, as the fragrance for incense using the fragrant material, it is preferable to use 0.1 to 2.0% in the composition of the preparation.

The oral composition of the present invention can be applied to a container such as an aluminum laminate tube, a tube such as a glass evaporated plastic tube, a dispenser container by mechanical or differential pressure, a bottle container such as polyethylene terephthalate or glass, or a film packaging container such as a pillow can do.

Example

Hereinafter, the present invention will be described in detail with reference to Examples, Comparative Examples and Prescription Examples, but the present invention is not limited to the following Examples. In the following examples, the amounts are all% by mass. The raw materials used were those conforming to cosmetic raw material standards or non-pharmaceutical quasi raw material specifications except those shown in Table 1. The composition of the fragrance is as shown in Tables 9 to 15. In addition, ethylene oxide was abbreviated as EO and polyoxyethylene was abbreviated as POE.

[Table 1]

Ingredients used in the preparation of oral compositions

[Examples, Comparative Examples]

(A) to (C), (D) or (E) and further (F) in a kind and a blending amount as shown in Tables 3 to 8 The dentifrice composition of the composition was degassed and mixed using a kneader and prepared by a routine method. The putting amount of the dentifrice composition was 5 kg. The obtained dentifrice composition was filled in a tube (A) of a material described later and evaluated by the following method. The results are shown in Tables 3-8.

Tube A (manufactured by Dainippon Printing Co., Ltd.):

(Thickness 257 占 퐉, diameter 26 mm, filling amount 50 g), LDPE 60 /

The numerical values represent the thickness (mu m). The abbreviations are as follows.

LDPE: Low density polyethylene

White LDPE: white low density polyethylene

LLDPE: linear low density polyethylene

AL: Aluminum

PET: Polyethylene terephthalate

EMAA: copolymer resin of ethylene / methacrylic acid

Evaluation of Periodontal Disease Inhibitory Effect

Using a beagle dog (4 years old, female) and 4 mice in each group, the bad breath and the amount of GCF were evaluated with an index. Evaluation of bad breath and measurement of the amount of GCF were carried out before the start of the test, and then administered twice a day for one month to evaluate the amount of halitosis and the amount of GCF. For the administration of the test agent, 0.5 g of the test agent was applied to a skimmed agent, 0.5 ml of a salve agent was applied to cotton balls, and the entire oral cavity of the beagle dog was brushed. Details of the evaluation method are shown below.

Assessment of bad breath from periodontal disease:

The bad breath at the start of the test was evaluated by five acupuncturists according to the criteria described below, and the score was set as S1. After administering the test preparation for one month, the level of halitosis originating from periodontal disease was evaluated according to the criterion described below by a 5th person in the same manner, and the score was evaluated as S2. According to the following equation, the degree of improvement of bad breath derived from periodontal disease of each beagle dog was calculated and the average value of four beagle dogs was obtained.

Improvement of bad breath from periodontal disease = S1 - S2

This average value was judged according to the criteria described later. It was judged that the composition for oral cavity of the improvement degree of bad breath derived from periodontal disease is?,?, Which is an oral composition having an effect of preventing or improving periodontal disease.

5: Very strong bad breath from periodontal disease

4: There is strong bad breath from periodontal disease.

3: There are a few bad breath from periodontal disease

2: Bad breath from periodontal disease is rare.

1: Bad breath from periodontal disease

0: No periodontal disease from periodontal disease

Improvement of bad breath from periodontal disease

?: Not less than 3 but not more than 5

?: 2 to less than 3

?: Not less than 1 and not more than 2

×: less than 1

Assessment of Periodontal Disease Prevention by Gingival Leachate (GCF) as an Index:

The lower part of the beagle dog (P3, P4, M1 mesio, M2 distal) was used as the test site, and the amount of GCF was measured before and after the start of the test. The collection of the GCF was performed after the bad breath was evaluated. The amount of GCF was determined by inserting GCF collection strips (PerioPaper (registered trademark), Yoshida) into the puncture pockets of the test site selected at the start of the test for 30 seconds and measuring the amount of GCF by using a GCF meter Lt; / RTI > Yoshida). The GCF change rate was calculated according to the following formula, and the average value of the four test sites of four beagle dogs was determined according to the criteria described below. The oral compositions of? And? Were evaluated for the periodontal disease prevention effect .

GCF change rate (%) =

((Amount of GCF at the start of the test - amount of GCF at the end of the test) / amount of GCF at the start of the test) × 100

GCF rate of change

◎: 70% or more

○: 40% or more and less than 70%

?: 20% or more and less than 40%

×: less than 20%

Evaluation of storage stability with time of ascorbic acid phosphate ester or its salt:

The test sample was stored in a thermostatic chamber at 50 캜 for 1 month. Thereafter, the sample was allowed to stand at room temperature, and then used for evaluation of storage stability of ascorbic acid phosphate or a salt thereof. The residual ratio was calculated from the initial value of the day of manufacture. The reagents were all made by Kanto Chemical.

When the test agent is a skimmed agent, 0.1 g is taken in a similar manner, and 10 mmol / l phosphate buffer (1.5 mmol / l potassium dihydrogen phosphate, 23.5 mmol / l dipotassium hydrogen phosphate, pH 8.0) Ester or its salt was extracted and subjected to high performance liquid chromatography (Pump: Japanese Spectroscopy PU1580, Auto Sampler: Shimadzu SIL-10A, UV detector: Shimadzu Seisakusho SPD-6A, Recording Device: Shimazu Seisakusho C- Spectrophotometer CO-966), the quantification was carried out by the absolute calibration curve method. The mobile phase was a stainless steel tube having a diameter of about 4.6 mm and a length of about 150 mm and a column of 5 탆 for a liquid chromatograph for a liquid chromatograph (25 mmol / ℓ potassium dihydrogenphosphate + 5 mmol / l tetrabutylammonium / acetonitrile = 91/9 mixture ratio Column temperature of about 40 占 폚, a detection wavelength of 240 nm, and a flow rate of 0.8 ml / min. The reaction was carried out in the same manner as in Example 1, In the case of the detergent, dilution was carried out with 10 mmol / l of phosphate buffer, and the measurement was carried out under the same conditions. The results were evaluated according to criteria described later, and it was judged that the oral composition of? And? Was preserved in storage stability of the ascorbic acid phosphate salt.

Residual ratio (%) of ascorbic acid phosphate ester or its salt =

(Evaluation sample value (%) / initial value (%)) x 100

The stability of ascorbic acid phosphoric acid ester or its salt was evaluated by the following three criteria.

Residual ratio of ascorbic acid phosphate ester or its salt

◎: 95% or more

○: Less than 95%

?: Less than 90%

×: less than 80%

Evaluation of storage stability with time of vitamin E or its derivatives:

The test sample was stored in a thermostat at 50 占 폚 for 1 month. The resulting mixture was allowed to stand at room temperature, and then 10 g of the preparation was applied to a skimmed or oral pasta. The resulting mixture was extracted with methanol and subjected to liquid chromatography (Pump: Nippon Spectroscopy PU-980, 950, detector: Japanese Spectrophotometer UV-970, recording apparatus: system instrument Chromatocoder 21J, column thermostatic chamber: Japanese spectrophotometer CO-966). Measurement conditions were as follows: Columns were packed with a stainless steel tube having an inner diameter of 4.6 mm and a length of 15 cm and containing 5 占 퐉 of octadecylsilylated silica gel for a liquid chromatograph using methanol as a mobile phase at a column temperature of 25 占 폚, 1.0 ml / Min to an ultraviolet light intensity (measurement wavelength: 284 nm) at a flow rate of 1 / min. In the case of the detergent, the sample was diluted with methanol, and the measurement was carried out under the same conditions. This result was judged according to the criterion described later, and it was judged that the oral composition of? And? Had the storage stability of the vitamin E derivative secured.

Residual ratio (%) of vitamin E or its derivative =

(Evaluation sample value (%) / initial value (%)) x 100

The stability of vitamin E or its derivatives was evaluated by the following three criteria.

Residual ratio of vitamin E or its derivative

◎: 95% or more

○: 90% or more and less than 95%

?: 80% or more and less than 90%

×: less than 80%

Evaluation of sterilizing power:

Forty-one microliters of the Porphyromonas jinx valis culture, which had been frozen and preserved, was added to each well of a Becton and Dickinson broth containing 5 mg / l hemin (Sigma) and 1 mg / l vitamin K (manufactured by Wako Pure Chemical Industries) (OD660) = 1 at a wavelength of 660 nm, followed by incubation at 37 占 폚 with diazo-anaerobic cultivation (80 vol% nitrogen, 10 vol% carbon dioxide, 10 vol% hydrogen) ).

In the case where the preparation is a skirt, 40 ml of artificial saliva is added to 10 g of the composition, and the mixture is stirred. After centrifugation (10,000 rpm, 10 minutes), the obtained supernatant is used as a sample solution. In the case of the preparation preparation, 40 ml of artificial saliva was added to 10 g of the composition to dilute it, and used as a sample stock solution. 2 ml of this undiluted sample solution was allowed to act on 2 ml of the bacterial solution for 30 seconds, and 50 占 퐇 was collected and used as a sample solution for evaluation of bactericidal effect. The bactericidal activity was evaluated by measuring the turbidity (OD660) as an indicator by adding the 50 占 퐇 of the bactericidal activity evaluation sample to the THB liquid medium (4 ml) and culturing (37 占 폚, 8 hours) Was evaluated as having a higher sterilizing power.

As artificial saliva, 3.73 g of potassium chloride, 0.14 g of monobasic potassium dihydrogen phosphate, 0.15 g of calcium chloride dihydrate and 0.02 g of magnesium chloride hexahydrate were dissolved in purified water and the pH was adjusted to 7 And adjusted to 1,000 ml was used.

◎: OD660 is less than 1

○: OD660 is 1 or more and less than 1.2

?: OD660 is 1.2 or more and less than 2

X: OD660 of 2 or more

Evaluation of appearance stability (separation, discoloration) over time:

The test sample was stored in a thermostatic chamber at 50 캜 for 1 month. Thereafter, the sample was allowed to stand at room temperature, and then used for evaluation of appearance stability. In the case where the test sample was a soft skirt, the sample was extruded about 10 cm on a straw paper (straw paper), and the presence or absence of separation and discoloration was observed and evaluated. In the case where the test sample was a three-mouth remedy, the container was left to stand for one day, and then the presence or absence of separation and discoloration was observed and evaluated. In addition, the discoloration was evaluated based on the object stored in the thermostatic chamber at 5 캜. The evaluation criteria are as follows.

◎: No separation is recognized at all

○: Little separation is recognized

?: A little separation is recognized

X: Significant separation is recognized

◎: No discoloration is recognized at all

○: discoloration is hardly recognized

?: Slight discoloration is recognized

X: Significant discoloration is recognized

[Table 2]

Common composition

[Table 3-1]

[Table 3-2]

[Table 4-1]

[Table 4-2]

From the results shown in Tables 3 and 4, it can be seen that the oral composition of the present invention is effective for the prevention of periodontal disease, the prevention of periodontal disease using GCF as an index, the sterilizing power, ascorbic acid phosphate or its salt and vitamin E or It has been found that the derivatives are excellent in preservation stability over time and appearance stability (no separation, no discoloration), exhibiting a high periodontal disease prevention or improvement effect, and superior in storage stability over time. If any one of the components (A), (B) and (D) is missing, or if the total amount of these components or the ratio of (C) / (B) + (D) Or when the number of moles of the alkyl group of the surfactant or the number of moles of the EO added is inadequate, the effect of any one of the above-mentioned effects is inferior and the action and effect of the present invention can not be achieved. Comparative Example 12 is a reproduction of Example 23 of JP-A-2005-187333, but the action and effect of the present invention could not be attained. The same results were obtained even when the fragrance B to I were used instead of the fragrance A.

[Table 5-1]

[Table 5-2]

[Table 6-1]

[Table 6-2]

From the results shown in Tables 5 and 6, it can be seen that the oral composition of the present invention is effective for preventing the bad breath caused by periodontal disease, preventing periodontal disease using GCF as an index, sterilizing power, ascorbic acid phosphate or its salt and vitamin E or It has been found that the derivatives are excellent in preservation stability over time and appearance stability (no separation, no discoloration), exhibiting a high periodontal disease prevention or improvement effect, and superior in storage stability over time. When either of the components (A), (B) and (E) is missing or the total amount of these components or the ratio of (C) / (B) + (E) Or when the alkyl chain of the surfactant or the average molar number of addition of EO is inadequate, the effect of the above-described one is inferior and the action and effect of the present invention can not be achieved. Comparative Example 25 is a reproduction of Example 9 of Japanese Patent Application Laid-Open No. 2005-247786, but the action and effect of the present invention could not be attained. The same results were obtained even when the fragrance B to I were used instead of the fragrance A.

[Table 7]

[Table 8]

From the results of Tables 7 and 8, it can be seen that the oral composition of the present invention can be obtained by incorporating glycyrrhetinic acid,? -Aminocaproic acid, glycyrrhizinate, tranexamic acid, yellow white extract or allantoin, It was found that the periodontal disease prevention and improvement effect was improved. The same results were obtained even when the fragrance B to I were used instead of the fragrance A.

[Table 9]

[Table 10]

[Table 11]

[Table 12]

[Table 13]

[Table 14]

[Table 15]

Hereinafter, a prescription example using the present invention will be shown.

The oral composition of the following composition was prepared and evaluated in the same manner as described above. As a result, it was found that any of the oral compositions showed a preventive effect against bad breath derived from periodontal disease, a periodontal disease prevention effect using GCF as an index, Storage stability of salt, storage stability of vitamin E or its derivative, sterilizing power, and appearance stability (no separation, no discoloration) were excellent. In addition, the dextrinase-containing composition was excellent in the effect of removing plaque and the composition containing fluoride ion source was also effective in preventing or improving hard tissue caries.

[Prescription Example 1]

(A) L-ascorbyl phosphate 0.3%

(B) dl -? - tocopherol acetate 0.1

(C) POE stearyl ether 1

(EO average addition mole number 5)

(C) POE hardened castor oil 1

(EO average addition mole number 20)

(D) isopropylmethylphenol 0.05

beta -glycetic acid 0.05

Dextranase (13,000 units / g) 0.16

Sodium fluoride 0.21

Sodium lauryl sulfate 1.5

Precipitated silica 15

Thick viscous silica 4

Xanthan gum 0.5

Carrageenan 0.5

Sodium polyacrylate 0.2

70% sorbitol solution 45

Propylene glycol 3

Sodium hydroxide 0.4

Saccharin sodium 0.15

Titanium oxide 0.5

Fragrance A 1

Blue No. 1 0.0001

Purified water balance

Total 100.00%

A + B + D = 0.45%

C / (B + D) = 13.3

[Prescription Example 2]

(A) L-ascorbyl phosphate 0.3%

(B) dl -? - tocopherol acetate 0.1

(C) POE stearyl ether 1

(EO average addition mole number 5)

(C) POE hardened castor oil 1

(EO average addition mole number 20)

(D) isopropylmethylphenol 0.05

beta -glycetic acid 0.05

Dextranase (13,000 units / g) 0.16

Sodium monofluorophosphate 0.73

Sodium lauryl sulfate 1.5

Precipitated silica 15

Thick viscous silica 4

Xanthan gum 0.5

Carrageenan 0.5

Sodium polyacrylate 0.2

70% sorbitol solution 45

Propylene glycol 3

Sodium hydroxide 0.4

Saccharin sodium 0.15

Titanium oxide 0.5

Fragrance A 1

Blue No. 1 0.0001

Purified water balance

Total 100.00%

A + B + D = 0.45%

C / (B + D) = 13.3

[Prescription Example 3]

(A) L-ascorbyl phosphate 0.3%

(B) dl -? - tocopherol acetate 0.1

(C) POE stearyl ether 1

(EO average addition mole number 5)

(C) POE hardened castor oil 1

(EO average addition mole number 20)

(E) Cetylpyridinium chloride 0.01

beta -glycetic acid 0.05

Dextranase (13,000 units / g) 0.16

Sodium fluoride 0.21

Sodium lauryl sulfate 1.5

Precipitated silica 15

Thick viscous silica 4

Xanthan gum 0.5

Carrageenan 0.5

Sodium polyacrylate 0.2

70% sorbitol solution 45

Propylene glycol 3

Sodium hydroxide 0.4

Saccharin sodium 0.15

Titanium oxide 0.5

Fragrance A 1

Blue No. 1 0.0001

Purified water balance

Total 100.00%

A + B + E = 0.41%

C / (B + E) = 12.7

[Prescription Example 4]

(A) L-ascorbyl phosphate 0.3%

(B) dl -? - tocopherol acetate 0.1

(C) POE stearyl ether 1

(EO average addition mole number 5)

(C) POE hardened castor oil 1

(EO average addition mole number 20)

(E) Cetylpyridinium chloride 0.01

beta -glycetic acid 0.05

Dextranase (13,000 units / g) 0.16

Sodium monofluorophosphate 0.73

Sodium lauryl sulfate 1.5

Precipitated silica 15

Thick viscous silica 4

Xanthan gum 0.5

Carrageenan 0.5

Sodium polyacrylate 0.2

70% sorbitol solution 45

Propylene glycol 3

Sodium hydroxide 0.4

Saccharin sodium 0.15

Titanium oxide 0.5

Fragrance A 1

Blue No. 1 0.0001

Purified water balance

Total 100.00%

A + B + E = 0.41%

C / (B + E) = 12.7

[Prescription Example 5]

(A) L-ascorbyl phosphate magnesium 0.5%

(B) dl -? - tocopherol acetate 0.1

(C) decyl glucoside 1

(C) lauryl glucoside 1

(E) cetylpyridinium chloride 0.05

Sodium monofluorophosphate 0.7

Sodium lauryl sulfate 1.5

Calcium Hydrogen Phosphate for Skins 40

Thick viscous silica 4

Xanthan gum 0.5

Carrageenan 0.5

Sodium polyacrylate 0.2

70% sorbitol solution 20

Palatine 2

Propylene glycol 3

Sodium hydroxide 0.4

Saccharin sodium 0.15

Titanium oxide 0.5

Fragrance A 1

Purified water balance

Total 100.00%

A + B + E = 0.65%

C / (B + E) = 13.3

[Prescription Example 6]

(A) L-ascorbyl phosphate magnesium 0.5%

(B) dl -? - tocopherol acetate 0.1

(C) decyl glucoside 1

(C) lauryl glucoside 1

(E) cetylpyridinium chloride 0.05

Sodium fluoride 0.21

Sodium lauryl sulfate 1.5

Calcium Hydrogen Phosphate for Skins 40

Thick viscous silica 4

Xanthan gum 0.5

Carrageenan 0.5

Sodium polyacrylate 0.2

70% sorbitol solution 20

Palatine 2

Propylene glycol 3

Sodium hydroxide 0.4

Saccharin sodium 0.15

Titanium oxide 0.5

Fragrance A 1

Purified water balance

Total 100.00%

A + B + E = 0.65%

C / (B + E) = 13.3

[Prescription Example 7]

(A) L-ascorbyl phosphate magnesium 0.5%

(B) dl -? - tocopherol acetate 0.1

(C) Polyoxyethylene hydrogenated castor oil 2

(EO average addition mole number 20)

(E) Benzethonium chloride 0.05

beta -glycetic acid 0.05

Sodium monofluorophosphate 0.7

Sodium lauryl sulfate 1.5

Calcium carbonate 40

Thick viscous silica 4

Xanthan gum 0.5

Carrageenan 0.5

Sodium polyacrylate 0.2

70% sorbitol solution 20

Erythritol 2

Propylene glycol 3

Sodium hydroxide 0.4

Saccharin sodium 0.15

Titanium oxide 0.5

Fragrance A 1

Purified water balance

Total 100.00%

A + B + E = 0.65%

C / (B + E) = 13.3

[Prescription Example 8]

(A) L-ascorbyl phosphate magnesium 0.5%

(B) nicotinic acid dl-a-tocopherol 0.1

(C) lauryl glucoside 1

(E) Cetylpyridinium chloride 0.01

beta -glycetic acid 0.2

Dextranase (13,000 units / g) 0.2

Sodium lauryl sulfate 0.5

Ethanol 10

Glycerin 10

Sodium hydroxide 0.4

Saccharin sodium 0.01

Perfume A 0.5

Purified water balance

Total 100.00%

A + B + E = 0.61%

C / (B + E) = 9.1

[Prescription Example 9]

(A) L-ascorbyl phosphate magnesium 0.5%

(B) nicotinic acid dl-a-tocopherol 0.1

(C) Polyoxyethylene hydrogenated castor oil 1

(EO average addition mole number 60)

(E) Cetylpyridinium chloride 0.01

beta -glycetic acid 0.2

Dextranase (13,000 units / g) 0.2

Sodium lauryl sulfate 0.5

Ethanol 10

Glycerin 10

Sodium hydroxide 0.4

Saccharin sodium 0.01

Perfume A 0.5

Purified water balance

Total 100.00%

A + B + E = 0.61%

C / (B + E) = 9.1

Claims

(A) 0.05 to 0.8% by mass of ascorbic acid phosphoric acid ester or its salt,
(B) 1 < / RTI > selected from d- alpha -tocopherol, dl- alpha -tocopherol, beta -tocopherol, gamma -tocopherol, delta -tocopherol and their acetic acid esters, nicotinic acid esters, succinic acid esters and linolenic acid esters, 0.05 to 0.5% by mass or more of two or more kinds of vitamin E or a derivative thereof,
(C) a polyoxyethylene hydrogenated castor oil having an average addition mole number of ethylene oxide of 10 to 60 moles, a polyoxyethylene alkyl ether having an alkyl group of 14 to 18 carbon atoms and an average addition mole number of ethylene oxide of 5 to 8 moles, 0.5 to 5% by mass of at least one surfactant selected from alkyl glucosides having 10 to 14 carbon atoms,
(D) isopropylmethylphenol 0.01-0.3 mass%
(A), (B) and (D) is from 0.2 to 1.5% by mass and the ratio of (C) / (B) + (D) &Lt; / RTI >

The method according to claim 1,
(C) / [(B) + (D)] is contained in an amount of from 8 to 15 in terms of a mass ratio, and the total content of the component (A), the component (B) Wherein the composition is an oral composition.

The method according to claim 1,
The composition for oral use according to claim 1, further comprising (F) 0.01 to 0.5% by mass of at least one selected from glycyrrhetinic acid,? -Aminocaproic acid, glycyrrhizinate, tranexamic acid, yellow white extract and allantoin.

The method according to claim 1,
Wherein the composition is a tooth dentifrice or a mouthwash.

delete